Serotonin and interleukin-6: The role of genetic polymorphisms in IFN-induced neuropsychiatric symptoms

Psychoneuroendocrinology

Volumn 38, Issue 9, 2013, Pages 1803-1813

  Udina, Marc ^a,b   Moreno España, José ^a,b,c   Navinés, Ricard ^a,b,d   Giménez, Dolors ^e   Langohr, Klaus ^d,f   Gratacòs, Mònica ^g   Capuron, Lucile ^c   de la Torre, Rafael ^d   Solà, Ricard ^e   Martín Santos, Rocío ^a,b,d  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c NutriNeuro Bordeaux University   (France)

^d HOSPITAL DEL MAR   (Spain)

^e UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^f UNIVERSITAT POLITÈCNICA DE CATALUNYA   (Spain)

^g CENTRE FOR GENOMIC REGULATION CRG   (Spain)

Author keywords

5 HTTLPR; Anxiety; Depression; Fatigue; Genetic; Hepatitis C; IL 6; Interferon alpha; Rs1800795; SERT

Indexed keywords

INTERLEUKIN 6; PEGINTERFERON ALPHA2A; RIBAVIRIN; SEROTONIN; SEROTONIN TRANSPORTER;

ADULT; ANXIETY; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DEPRESSION; DSM-IV; FATIGUE; FEMALE; GENE INTERACTION; GENE LOCATION; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; INTERLEUKIN 6 GENE; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHIATRY; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROMOTER REGION; SEROTONIN TRANSPORTER GENE; STRUCTURED CLINICAL INTERVIEW FOR DSM DISORDERS; VISUAL ANALOG SCALE;

5-HTTLPR; ANXIETY; DEPRESSION; FATIGUE; GENETIC; HEPATITIS C; IL-6; INTERFERON ALPHA; RS1800795; SERT;

ADULT; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANTIVIRAL AGENTS; ANXIETY; COHORT STUDIES; DEPRESSION; DRUG THERAPY, COMBINATION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FATIGUE; GENETIC PREDISPOSITION TO DISEASE; HEPATITIS C, CHRONIC; HUMANS; INDEL MUTATION; INTERFERON-ALPHA; INTERLEUKIN-6; MIDDLE AGED; POINT MUTATION; POLYETHYLENE GLYCOLS; PROMOTER REGIONS, GENETIC; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RIBAVIRIN; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 84883656201     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2013.03.007     Document Type: Article

References (62)

1. Anisman H. Cascading effects of stressors and inflammatory immune system activation: implications for major depressive disorder. J. Psychiatry Neurosci. 2009, 34:4-20.
2. Avula R., Rand A., Black J.L., O'Kane D.J. Simultaneous genotyping of multiple polymorphisms in human serotonin transporter gene and detection of novel allelic variants. Transl. Psychiatry 2011, 1:e32.
3. Belluco C., Olivieri F., Bonafe M., Giovagnetti S., Mammano E., Scalerta R., Ambrosi A., Franceschi C., Nitti D., Lise M. -174 G>C polymorphism of interleukin 6 gene promoter affects interleukin 6 serum level in patients with colorectal cancer. Clin. Cancer Res. 2003, 9:2173-2176.
4. Bonaccorso S., Puzella A., Marino V., Pasquini M., Biondi M., Artini M., Almerighi C., Levrero M., Egyed B., Bosmans E., Meltzer H.Y., Maes M. Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Psychiatry Res. 2001, 105:45-55.
5. Bufalino C., Hepgul N., Aguglia E., Pariante C.M. The role of immune genes in the association between depression and inflammation: a review of recent clinical studies. Brain Behav. Immun. 2012, 10.1016/j.bbi.2012.04.009.
6. Bull S.J., Huezo-Diaz P., Binder E.B., Cubells J.F., Ranjith G., Maddock C., Miyazaki C., Alexander N., Hotopf M., Cleare A.J., Norris S., Cassidy E., Aitchison K.J., Miller A.H., Pariante C.M. Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment. Mol. Psychiatry 2009, 14:1095-1104.
7. Cai W., Khaoustov V.I., Xie Q., Pan T., Le W., Yoffe B. Interferon-alpha-induced modulation of glucocorticoid and serotonin receptors as a mechanism of depression. J. Hepatol. 2005, 42:880-887.
8. Capuron L., Ravaud A., Gualde N., Bosmans E., Dantzer R., Maes M., Neveu P.J. Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy. Psychoneuroendocrinology 2001, 26:797-808.
9. Capuron L., Gumnick J.F., Musselman D.L., Lawson D.H., Reemsnyder A., Nemeroff C.B., Miller A.H. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002, 26:643-652.
10. Capuron L., Pagnoni G., Demetrashvili M.F., Lawson D.H., Fornwalt F.B., Woolwine B., Berns G.S., Nemeroff C.B., Miller A.H. Basal ganglia hypermetabolism and symptoms of fatigue during interferon-alpha therapy. Neuropsychopharmacology 2007, 32:2384-2392.
11. Carlo-Stella N., Badulli C., De Silvestri A., Bazzichi L., Martinetti M., Lorusso L., Bombardieri S., Salvaneschi L., Cuccia M. A first study of cytokine genomic polymorphisms in CFS: positive association of TNF-857 and IFNgamma 874 rare alleles. Clin. Exp. Rheumatol. 2006, 24:179-182.
12. Caspi A., Sugden K., Moffitt T.E., Taylor A., Craig I.W., Harrington H., McClay J., Mill J., Martin J., Braithwaite A., Poulton R. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003, 301:386-389.
13. Collantes R.S., Younossi Z.M. The use of growth factors to manage the hematologic side effects of PEG-interferon alfa and ribavirin. J. Clin. Gastroenterol. 2005, 39:9-13.
14. Dantzer R. Cytokine-induced sickness behavior: where do we stand?. Brain Behav. Immun. 2001, 15:7-24.
15. Dantzer R., O'Connor J.C., Lawson M.A., Kelley K.W. Inflammation-associated depression: from serotonin to kynurenine. Psychoneuroendocrinology 2011, 36:426-436.
16. Demirkan A., Penninx B.W., Hek K., Wray N.R., Amin N., Aulchenko Y.S., van Dyck R., de Geus E.J., Hofman A., Uitterlinden A.G., Hottenga J.J., Nolen W.A., Oostra B.A., Sullivan P.F., Willemsen G., Zitman F.G., Tiemeier H., Janssens A.C., Boomsma D.I., van Duijn C.M., Middeldorp C.M. Genetic risk profiles for depression and anxiety in adult and elderly cohorts. Mol. Psychiatry 2011, 16:773-783.
17. Eyre H., Baune B.T. Neuroplastic changes in depression: a role for the immune system. Psychoneuroendocrinology 2012, 37:1397-1416.
18. Fallarino F., Grohmann U., Puccetti P. Indoleamine 2,3-dioxygenase: from catalyst to signaling function. Eur. J. Immunol. 2012, 42:1932-1937.
19. First M.B., Spitzer R.L., Williams J.B. Structured Clinical Interview for DSM-IV (SCID-I) (User's Guide and Interview) Research Version 1995, Biometrics Research Department, New York Psychiatric Institute, Ed New York.
20. Fishman D., Faulds G., Jeffery R., Mohamed-Ali V., Yudkin J.S., Humphries S., Woo P. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J. Clin. Invest. 1998, 102:1369-1376.
21. Franzen P.L., Buysse D.J., Rabinovitz M., Pollock B.G., Lotrich F.E. Poor sleep quality predicts onset of either major depression or subsyndromal depression with irritability during interferon-alpha treatment. Psychiatry Res. 2010, 177:240-245.
22. Goebel M.U., Baase J., Pithan V., Exton M., Saller B., Schedlowski M., Limmroth V. Acute interferon beta-1b administration alters hypothalamic-pituitary-adrenal axis activity, plasma cytokines and leukocyte distribution in healthy subjects. Psychoneuroendocrinology 2002, 27:881-892.
23. Gonda X., Fountoulakis K.N., Harro J., Pompili M., Akiskal H.S., Bagdy G., Rihmer Z. The possible contributory role of the S allele of 5-HTTLPR in the emergence of suicidality. J. Psychopharmacol. 2011, 25:857-866.
24. Hariri A.R., Mattay V.S., Tessitore A., Kolachana B., Fera F., Goldman D., Egan M.F., Weinberger D.R. Serotonin transporter genetic variation and the response of the human amygdala. Science 2002, 297:400-403.
25. Heils A., Teufel A., Petri S., Stober G., Riederer P., Bengel D., Lesch K.P. Allelic variation of human serotonin transporter gene expression. J. Neurochem. 1996, 66:2621-2624.
26. Herrero M.J., Blanch J., Peri J.M., De Pablo J., Pintor L., Bulbena A. A validation study of the hospital anxiety and depression scale (HADS) in a Spanish population. Gen. Hosp. Psychiatry 2003, 25:277-283.
27. Howren M.B., Lamkin D.M., Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom. Med. 2009, 71:171-186.
28. Jacobson I.M., McHutchison J.G., Dusheiko G., Di Bisceglie A.M., Reddy K.R., Bzowej N.H., Marcellin P., Muir A.J., Ferenci P., Flisiak R., George J., Rizzetto M., Shouval D., Sola R., Terg R.A., Yoshida E.M., Adda N., Bengtsson L., Sankoh A.J., Kieffer T.L., George S., Kauffman R.S., Zeuzem S. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 2011, 364:2405-2416.
29. Kim H., Chen L., Lim G., Sung B., Wang S., McCabe M.F., Rusanescu G., Yang L., Tian Y., Mao J. Brain indoleamine 2,3-dioxygenase contributes to the comorbidity of pain and depression. J. Clin. Invest. 2012, 122:2940-2954.
30. Kraus M.R., Al-Taie O., Schäfer A., Pfersdorff M., Lesch K.-P., Scheurlen M. Serotonin-1A receptor gene HTR1A variation predicts interferon-induced depression in chronic hepatitis C. Gastroenterology 2007, 132:1279-1286.
31. Kwo P.Y., Lawitz E.J., McCone J., Schiff E.R., Vierling J.M., Pound D., Davis M.N., Galati J.S., Gordon S.C., Ravendhran N., Rossaro L., Anderson F.H., Jacobson I.M., Rubin R., Koury K., Pedicone L.D., Brass C.A., Chaudhri E., Albrecht J.K. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010, 376:705-716.
32. Lesch K.P., Bengel D., Heils A., Sabol S.Z., Greenberg B.D., Petri S., Benjamin J., Muller C.R., Hamer D.H., Murphy D.L. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996, 274:1527-1531.
33. Lotrich F.E., Albusaysi S., Ferrell R.E. Brain-derived neurotrophic factor serum levels and genotype: association with depression during interferon-alpha treatment. Neuropsychopharmacology 2012, 10.1038/npp.2012.263.
34. Lotrich F.E., Ferrell R.E., Rabinovitz M., Pollock B.G. Risk for depression during interferon-alpha treatment is affected by the serotonin transporter polymorphism. Biol. Psychiatry 2009, 65:344-348.
35. Lotrich F.E., Loftis J.M., Ferrell R.E., Rabinovitz M., Hauser P. IL28B polymorphism is associated with both side effects and clearance of hepatitis C during interferon-alpha therapy. J. Interferon Cytokine Res. 2010, 10.1089/jir.2010.0074.
36. Maekawa S., Enomoto N. Viral factors influencing the response to the combination therapy of peginterferon plus ribavirin in chronic hepatitis C. J. Gastroenterol. 2009, 44:1009-1015.
37. Martín-Santos R., Díez-Quevedo C., Castellví P., Navinés R., Miquel M., Masnou H., Soler A., Ardevol M., García F., Galeras J.A., Planas R., Solà R. De novo depression and anxiety disorders and influence on adherence during peginterferon-alpha-2a and ribavirin treatment in patients with hepatitis C. Aliment. Pharmacol. Ther. 2008, 27:257-265.
38. Martocchio J. Research in Personnel and Human Resources Management 2009, vol. 28. Emerald Group Publishing Limited, Cornell University.
39. O'Donovan A., Hughes B.M., Slavich G.M., Lynch L., Cronin M.T., O'Farrelly C., Malone K.M. Clinical anxiety, cortisol and interleukin-6: evidence for specificity in emotion-biology relationships. Brain Behav. Immun. 2010, 24(36):1074-1077.
40. Pearlman B.L. Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care. Lancet Infect. Dis. 2012, 12:717-728.
41. Pergamin-Hight L., Bakermans-Kranenburg M.J., van Ijzendoorn M.H., Bar-Haim Y. Variations in the promoter region of the serotonin transporter gene and biased attention for emotional information: a meta-analysis. Biol. Psychiatry 2012, 71:373-379.
42. Pierucci-Lagha A., Covault J., Bonkovsky H.L., Feinn R., Abreu C., Sterling R.K., Fontana R.J., Kranzler H.R. A functional serotonin transporter gene polymorphism and depressive effects associated with interferon-alpha treatment. Psychosomatics 2010, 51:137-148.
43. Prather A.A., Rabinovitz M., Pollock B.G., Lotrich F.E. Cytokine-induced depression during IFN-alpha treatment: the role of IL-6 and sleep quality. Brain Behav. Immun. 2009, 23:1109-1116.
44. Raison C.L., Demetrashvili M., Capuron L., Miller A.H. Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs 2005, 19:105-123.
45. Raison C.L., Borisov A.S., Woolwine B.J., Massung B., Vogt G., Miller A.H. Interferon-alpha effects on diurnal hypothalamic-pituitary-adrenal axis activity: relationship with proinflammatory cytokines and behavior. Mol. Psychiatry 2010, 15:535-547.
46. Raison C.L., Broadwell S.D., Borisov A.S., Manatunga A.K., Capuron L., Woolwine B.J., Jacobson I.M., Nemeroff C.B., Miller A.H. Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C. Brain Behav. Immun. 2005, 19:23-27.
47. Raison C.L., Borisov A.S., Majer M., Drake D.F., Pagnoni G., Woolwine B.J., Vogt G.J., Massung B., Miller A.H. Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression. Biol. Psychiatry 2009, 65:296-303.
48. Raison C.L., Dantzer R., Kelley K.W., Lawson M.A., Woolwine B.J., Vogt G., Spivey J.R., Saito K., Miller A.H. CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. Mol. Psychiatry 2010, 15:393-403.
49. Riikola A., Sipila K., Kahonen M., Jula A., Nieminen M.S., Moilanen L., Kesaniemi Y.A., Lehtimaki T., Hulkkonen J. Interleukin-6 promoter polymorphism and cardiovascular risk factors: the Health 2000 Survey. Atherosclerosis 2009, 207:466-470.
50. Schiff E.R. Diagnosing and treating hepatitis c virus infection. Am. J. Manage. Care 2011, 17:S108-S115.
51. Serretti A., Kato M., De Ronchi D., Kinoshita T. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol. Psychiatry 2007, 12:247-257.
52. Smith A.K., Dimulescu I., Falkenberg V.R., Narasimhan S., Heim C., Vernon S.D., Rajeevan M.S. Genetic evaluation of the serotonergic system in chronic fatigue syndrome. Psychoneuroendocrinology 2008, 33:188-197.
53. Smith A.K., Simon J.S., Gustafson E.L., Noviello S., Cubells J.F., Epstein M.P., Devlin D.J., Qiu P., Albrecht J.K., Brass C.A., Sulkowski M.S., McHutchinson J.G., Miller A.H. Association of a polymorphism in the indoleamine-2,3-dioxygenase gene and interferon-α-induced depression in patients with chronic hepatitis C. Mol. Psychiatry 2011, 17:781-789.
54. Stahl S.M. Mechanism of action of serotonin selective reuptake inhibitors, serotonin receptors and pathways mediate therapeutic effects and side effects. J. Affect. Disord. 1998, 51:215-235.
55. Su K.-P., Huang S.-Y., Peng C.-Y., Lai H.-C., Huang C.-L., Chen Y.-C., Aitchison K.J., Pariante C.M. Phospholipase A2 and cyclooxygenase 2 genes influence the risk of interferon-alpha-induced depression by regulating polyunsaturated fatty acids levels. Biol. Psychiatry 2010, 67:550-557.
56. Udina M., Castellvi P., Moreno-Espana J., Navines R., Valdes M., Forns X., Langohr K., Sola R., Vieta E., Martin-Santos R. Interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis. J. Clin. Psychiatry 2012, 73:1128-1138.
57. Vollmer-Conna U., Fazou C., Cameron B., Li H., Brennan C., Luck L., Davenport T., Wakefield D., Hickie I., Lloyd A. Production of pro-inflammatory cytokines correlates with the symptoms of acute sickness behaviour in humans. Psychol. Med. 2004, 34:1289-1297.
58. Wasley A., Alter M.J. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin. Liver Dis. 2000, 20:1-16.
59. Wichers M.C., Kenis G., Leue C., Koek G., Robaeys G., Maes M. Baseline immune activation as a risk factor for the onset of depression during interferon-alpha treatment. Biol. Psychiatry 2006, 60:77-79.
60. Yee L.J., Im K., Borg B., Yang H., Liang T.J. Interleukin-6 haplotypes and the response to therapy of chronic hepatitis C virus infection. Genes Immun. 2009, 10:365-372.
61. Zakharyan R., Petrek M., Arakelyan A., Mrazek F., Atshemyan S., Boyajyan A. Interleukin-6 promoter polymorphism and plasma levels in patients with schizophrenia. Tissue Antigens 2012, 80:136-142.
62. Zigmond A.S., Snaith R.P. The hospital anxiety and depression scale. Acta Psychiatr. Scand. 1983, 67:361-370.